|
|
Article: BioMarck Pharmaceuticals Announces Safety Review of Phase 2 Study and Changes in Study Protocol.
- Article from:
- Clinical Trials Week
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioMarck Pharmaceuticals, Ltd., a research company involved in the treatment of respiratory diseases, announced that it has completed enrollment in the middle dose group of its ongoing Phase 2 clinical trial and that an independent safety monitoring committee recently reviewed the safety results from the middle dose group of the study. Based on this review, the monitoring committee recommended that BioMarck continue enrollment in the study, known as the BREATH 1 study (BIO-11006: Respiratory Effectiveness of A Targeted Therapeutic).
Following this positive review, BioMarck had planned to escalate to the last dose group in the study (i.e., the high dose group). ...